ACADEMISCH MEDISCH CENTRUM Patent applications |
Patent application number | Title | Published |
20150044167 | Means and Method for Response Prediction of Hepatitis B Treatment - The present invention provides means and methods for determining whether a hepatitis B patient is susceptible to hepatitis B treatment, comprising determining whether a sample of the patient comprises nucleic acid with nucleotide polymorphisms that are associated with a positive outcome of hepatitis B treatment and/or determining whether a sample of the patient comprises an expression level of carnitine or of a carnitine derivative that is associated with a positive outcome of hepatitis B treatment. Compositions, kits of parts, (micro)arrays and vectors useful for such methods are also herewith provided. | 02-12-2015 |
20140294774 | METHOD FOR PREVENTING AND/OR TREATING INSULIN RESISTANCE - Described is the use of | 10-02-2014 |
20130196443 | APPARATUS AND METHOD FOR DATING A BODY OR BODY SAMPLE - A method and apparatus for dating a dating a body sample, such as blood, includes taking at least one spectroscopic measurement ( | 08-01-2013 |
20130078632 | MATERIALS AND METHODS FOR PROGNOSIS OF PROGRESSION OF BARRETT'S ESOPHAGUS - A method of prognosticating progression of Barrett's esophagus in a patient comprising detecting in a sample of esophageal cells from the patient at least one abnormality selected from the group consisting of p16 loss, p53 loss, chromosome 7 aneuploidy, and chromosome 17 aneuploidy, which method can further comprise detecting at least one abnormality selected from the group consisting of 20q gain, C-myc gain, and Her2 gain; and a kit comprising (a) a set of probes comprising a probe for p16, a probe for p53, a probe for chromosome 7, and a probe for chromosome 17 and (b) instructions comprising determining at least one abnormality selected from the group consisting of p16 loss, p53 loss, chromosome 7 aneuploidy, and chromosome 17 aneuploidy, which kit can further comprise at least one additional probe selected from the group consisting of a probe for 20q, a probe for C-myc, and a probe for Her2 and additional instructions comprising determining at least one additional abnormality selected from the group consisting of 20q gain, C-myc gain, and Her2 gain. | 03-28-2013 |
20120164128 | MEANS AND METHODS FOR COUNTERACTING POLYQ EXPANSION DISORDERS - The present invention provides means and methods for counteracting and/or preventing aggregation of a polyQ protein. Further provided are improved poly constructs which are, amongst other things, useful for testing assays. According to the invention, several peptidases like, e.g. tripeptidyl peptidase II (TPPII), appear to be capable of cleaving long polyQ peptides comprising at least 45 glutamine residues. Hence, according to the invention, administration of such peptidases to an individual suffering from a polyQ expansion disorder results in degradation of long polyQ peptides. | 06-28-2012 |
20120041478 | Instrument for Minimally Invasive Surgery - An instrument for minimally invasive surgery suitable for use with a manipulator comprising a tube provided at its first end with a mouthpiece wherein control means for the mouthpiece pass through the tube, and wherein at a second end of the tube opposite to the first end comprising the mouthpiece control organs are provided that are coupled with the control means for the mouthpiece that are passing through the tube. | 02-16-2012 |
20110112385 | APPARATUS AND METHOD FOR DATING A BODY SAMPLE - A method and apparatus for dating a body sample, for example a sample of body fluid involves taking a series of spectroscopic measurements of the sample, each measurement in the series including at least two predetermined positions in the spectrum. The positions have spectral characteristics corresponding to two or more predetermined substances present in the sample that have a time varying relationship with each other. The measurements in the series are spaced in time. A concentration of each of the substances present in the sample is then determined from each of the spectroscopic measurements at each point in time. Next, a ratio of the concentrations of the two predetermined substances at each point in time is determined and then the ratios of the concentrations of the two predetermined substances over time are analysed to estimate when the concentrations of the two substances were at a limit of their concentrations, thereby providing an indication of the age of the sample. The sample may be blood, which may be either within the body (e.g. as a bruise), or external to the body. | 05-12-2011 |
20090186862 | TREATMENT OF CYSTIC FIBROSIS - The present invention discloses a therapeutic target for the treatment of cystic fibrosis. It was found that inhibition of non-lysosomal glucosylceramidase (GBA2) sufficiently restores chloride current in cells from CF patients carrying the common delF508-CFTR mutation. With the catalytic centre (4) of the enzyme positioned on top of the membrane bilayer face particularly potent inhibitors are found in deoxynojirimycin derivatives having a group that is capable of inserting in the membrane bilayer. | 07-23-2009 |
20090012378 | Pulsed Lighting Imaging Systems and Methods - Systems and methods for monitoring patients utilizing reflectance avoidance as well as other imaging modalities. Information regarding perfusion, oxygen saturation and oxygen availability, as well as others may be obtained. System embodiments may include a light source, a light transport body configured to project light from the light source to an examination substrate and transmit light reflected by the examination substrate, and an analysis section in optical communication with the light transport body. The light source may be pulsed in order to improve the quality of video images produced by the systems. | 01-08-2009 |